Equities Analysts Offer Predictions for SABS FY2024 Earnings

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Research analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for SAB Biotherapeutics in a report released on Thursday, November 7th. HC Wainwright analyst E. White now expects that the company will post earnings of ($3.75) per share for the year, down from their prior estimate of ($3.64). HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.64) per share. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q4 2024 earnings at ($1.30) EPS, FY2025 earnings at ($5.27) EPS and FY2026 earnings at ($4.01) EPS.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%.

A number of other analysts have also commented on SABS. Craig Hallum initiated coverage on SAB Biotherapeutics in a research note on Wednesday, October 9th. They set a “buy” rating and a $11.00 price objective on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $12.00 price target on shares of SAB Biotherapeutics in a research note on Thursday, September 12th. Finally, Chardan Capital reiterated a “buy” rating and issued a $25.00 price target on shares of SAB Biotherapeutics in a report on Thursday, November 7th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $12.40.

SAB Biotherapeutics Stock Performance

SABS stock opened at $3.19 on Monday. The stock’s 50 day moving average price is $2.90 and its 200 day moving average price is $2.99. The company has a quick ratio of 5.24, a current ratio of 3.69 and a debt-to-equity ratio of 0.09. SAB Biotherapeutics has a 1 year low of $2.16 and a 1 year high of $9.72.

Institutional Trading of SAB Biotherapeutics

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. First PREMIER Bank purchased a new stake in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 19,386 shares of the company’s stock, valued at approximately $60,000. First PREMIER Bank owned approximately 0.21% of SAB Biotherapeutics as of its most recent SEC filing. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.